<DOC>
	<DOCNO>NCT00651664</DOCNO>
	<brief_summary>This multicenter , dose escalation , phase 1 study MLN8237 adult patient advanced malignancy ( exclude primary bone marrow involvement , leukemias multiple myeloma ) .</brief_summary>
	<brief_title>A Phase I Clinical Pharmacodynamic Study MLN8237 , A Novel Aurora A Kinase Inhibitor , Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Have histologically cytologically confirm metastatic and/or advance malignancy ( include lymphoma exclude malignancy extensive bone marrow involvement leukemia multiple myeloma ) standard treatment offer curative lifeprolonging potential Aged 18 year Eastern Cooperative Oncology Group performance status 0 1 Have expect survival longer 3 month enrollment study Radiographically clinically evaluable tumor Suitable venous access conduct blood sampling Recovered reversible effect prior antineoplastic therapy ( exception alopecia grade 1 neuropathy ) least 4 week elapse since last exposure cytotoxic chemotherapy radiotherapy least 6 week elapse since exposure nitrosoureas mitomycin C. Male patient must use appropriate method barrier contraception inform sexual partner must also use reliable method contraception time inform consent 3 month last dose study treatment . Female patient must postmenopausal least 1 year , OR surgically sterile , OR childbearing potential , agree 2 effective method nonhormonal contraception , agree completely abstain heterosexual intercourse . Able give write consent . Pregnant lactate Major surgery serious infection within 28 day precede first dose study treatment Lifethreatening uncontrolled medical illness unrelated cancer Ongoing nausea vomit severity &gt; Grade 1 diarrhea . Patients require ongoing therapy antimotility agent control diarrhea Grade 1 low level allow participate trial Known gastrointestinal disease gastrointestinal procedure could interfere oral absorption tolerance MLN8237 . History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness severe chronic obstructive pulmonary disease . Difficulty swallow capsule Inability take nothing mouth except water prescribe medication 2 hour 1 hour dose MLN8237 Received 4 previous cytotoxic chemotherapeutic regimen , include regimen use adjuvant neoadjuvant therapy ( patient metastatic breast cancer , total 5 previous cytotoxic chemotherapeutic regimen permit ) . Prior treatment highdose chemotherapy , define chemotherapy require use peripheral blood bone marrow stem cell support hematopoietic reconstitution Prior treatment radiation therapy involve â‰¥25 % hematopoietically active bone marrow distribution active bone marrow adult ) Clinical and/or radiographic evidence cerebral metastasis . However , patient history central nervous system metastasis radiographic clinical evidence residual tumor ( eg , follow complete surgical resection stereotactic radiosurgery ) exclude participation study . Abnormalities 12lead electrocardiogram consider investigator clinically significant baseline prolongation ratecorrected QT interval ( eg , repeated demonstration QTc interval &gt; 450 millisecond ) . Known history human immunodeficiency virus ( HIV ) infection , hepatitis B hepatitis C. Less 4 week last dose investigational agent first dose MLN8237 . Admission evidence benzodiazepine dependence abuse and/or alcohol abuse inability restrict consumption alcohol 1 standard unit alcohol per day study 30 day last dose study treatment . aPTT and/or PT exceed upper limit normal range Known bleed diathesis history abnormal bleeding Ongoing therapy anticoagulant ( e.g. , aspirin , plavix , coumadin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>